Denali Therapeutics Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 101.8 million compared to USD 109.78 million a year ago. Basic loss per share from continuing operations was USD 0.68 compared to USD 0.8 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
20.23 USD | -1.37% | +5.13% | -5.45% |
08/05 | Stifel Adjusts Price Target on Denali Therapeutics to $22 From $26, Maintains Hold Rating | MT |
08/05 | Wedbush Adjusts Denali Therapeutics' Price Target to $30 From $31, Keeps Outperform Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.45% | 2.92B | |
+9.92% | 115B | |
+12.01% | 106B | |
-2.59% | 21.96B | |
-12.49% | 21.87B | |
-5.29% | 19.21B | |
-4.02% | 18.08B | |
-38.57% | 17.71B | |
+7.21% | 14.32B | |
+35.18% | 12.42B |
- Stock Market
- Equities
- DNLI Stock
- News Denali Therapeutics Inc.
- Denali Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024